Navigation Links
New chimeric mouse model for human liver diseases, drug testing
Date:12/4/2007

La Jolla, CA Cells cultured in the lab are like a fish out of water. Often, their behavior does not reflect their biological function within an entire organ or organism, which, for example, turns studying human liver cells into a big challenge.

One way to get around the altered properties of the stranded cells is to populate mouse livers with human hepatocytes in the hope of creating a natural environment, which is exactly what researchers at the Salk Institute for Biological Studies did. They developed a simple system that allows them to transplant human hepatocytes into immunodeficient mice, which can now be used to test how drugs affect the liver.

Rodents are often used as model organisms to study the efficacy and toxicity of drugs, says lead author Karl-Dimiter Bissig, M.D. Ph.D., a postdoctoral researcher in the Laboratory of Genetics, but mouse and rat hepatocytes may function in very different ways when it comes to metabolism of drugs.

In the past, this has led to unexpected toxicity problems, when drugs moved into clinical trials after toxicity tests in rats failed to reveal adverse effects (e.g. Troglitazone). But it also worked the other way around. The clinical introduction of furosamide, a powerful but perfectly safe diuretic, has been slowed down because of its hepatotoxicity in rats, says Bissig.

The work, which will be published in this weeks online edition of the Proceedings of the National Academy of Sciences also holds promise for a better understanding of infectious diseases that affect the liver. It is basically impossible to grow human hepatocytes in the lab, which was a big hurdle for the study of viruses such as hepatitis A and hepatitis B, says senior author Inder Verma, Ph.D., a professor in the Laboratory of Genetics.

But most importantly, Bissig says, the mice will be an invaluable tool to advance regenerative medicine. Many inherited disorders affecting liver metabolism could be cured if only five percent of all hepatocytes would express the missing enzyme, he says.

In fact, thats the underlying principle of the Salk researchers new chimeric mouse. It is based on a murine model for hereditary tyrosinaemia type I, developed by researchers at Oregon Healthy & Science University. An enzymatic defect in the tyrosine catabolism results in a toxic accumulation of byproducts within hepatocytes unless the mice are treated with a drug called NBTC.

Withdrawing the drug allows to selectively expand hepatocytes that do not have this defect, such as transplanted human hepatocytes. Within three months of transplantation, up to 20 percent of the mouse liver is repopulated by human hepatocytes. But whats more, the transplanted cells keep producing a foreign protein slipped inside with the help of a lentiviral vector, the kind usually used for gene therapy. We are very excited about that aspect since very often cells shut off the production of proteins introduced as part of gene therapy, says Verma.


'/>"/>

Contact: Gina Kirchweger
kirchweger@salk.edu
858-453-4100 x1340
Salk Institute  
Source:Eurekalert

Related biology news :

1. A computer for your mouse!
2. Immune cells promote blood vessel formation in mouse endometriosis
3. Cancer-resistant mouse discovered
4. Looking through the eyes of a mouse, scientists monitor circulating cells in its bloodstream
5. Novel 3-D cell culture model shows selective tumor uptake of nanoparticles
6. A new kind of rat model
7. JILA finds flaw in model describing DNA elasticity
8. Smithsonian researchers develop models to assess wetland health
9. Prediction of RNA pseudoknots using heuristic modeling with mapping and sequential folding
10. Simulating kernel production influences maize model accuracy
11. MIT model could improve some drugs effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New chimeric mouse model for human liver diseases, drug testing
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
Breaking Biology News(10 mins):
(Date:9/22/2017)... ... September 22, 2017 , ... ... Justin Zalewsky in offering LANAP® and LAPIP™ laser treatments. Drs. Hoge and Zalewsky ... to patients, a minimally invasive and less painful option that produces real results. ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... which includes executive, engineering and manufacturing functions to The LaunchPort™ Accelerator at the ... provide a full range of manufacturing and business services to its Residents. ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... clinical client portal. Each relaunch of the portal includes new features that facilitate ... medical device companies seek to remain at the forefront of medical advancements, they ...
(Date:9/21/2017)... ... September 21, 2017 , ... When a downtown Greenville ... was swift and efficient thanks to the continuing efforts of members of the ... more than 50 stakeholders, including officials from area counties and cities, Renewable Water ...
Breaking Biology Technology: